VKTX - Viking Therapeutics, Inc.
About Viking Therapeutics, Inc. (https://www.vikingtherapeutics.com)
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Brian Lian | President, Chief Executive Officer & Director | 1966 | $1,045,000 USD |
| Marianne Mancini | Chief Operating Officer | 1965 | $765,000 USD |
| Gregory S. Zante | Chief Financial Officer | 1971 | $738,000 USD |
| Michael Morneau | Vice President of Finance & Administration | 1965 | $375,333 USD |
| Geoffrey E. Barker | Chief Development Officer | – | – |
| Hubert C. Chen | Chief Medical Officer | 1969 | – |
| Katherine Mercier | Vice President of Quality and Compliance | – | – |
| Kenneth Herman | Senior Vice President of Commercial, Marketing & Sales | – | – |
| Neil Aubuchon | Chief Commercial Officer | 1970 | – |
| Nils U. Olsson | Senior Vice President of Technical Operations | – | – |